How NLRC4 signaling affects immune responses
Official title: Innate NLRC4 signaling controls adaptive immune responses
Funded at Cedars-Sinai Medical Center · NIH-11091629 · Data updated 2026-11-12
This study is looking at a protein called NLRC4 to see how it helps our immune system fight off diseases like cancer and viral infections, and the findings could help improve treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cedars-Sinai Medical Center NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | June 20, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $632,133 |
| NIH project number | 5R01AI177233-03 |
| Project ID | NIH-11091629 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with autoimmune diseases, cancer, or those at risk of severe viral infections.
✕Less likely to help
Patients with non-immune related conditions or those not affected by cancer or viral infections may not benefit from this research.
What this research studies
This research investigates the role of NLRC4, a protein involved in the immune system, particularly in how it influences the body's adaptive immune responses. By studying how NLRC4 interacts with immune cells, the research aims to understand its protective effects against conditions like cancer and viral infections. The approach includes examining the signaling pathways and cellular interactions that NLRC4 mediates, particularly focusing on its effects on T cells and antigen-presenting cells. Patients may benefit from insights gained into how to enhance immune responses against diseases.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for improving immune responses in patients with cancer or viral infections.
How similar studies have gone: Other research has shown promising results in understanding immune signaling pathways, suggesting potential for success in this novel approach.
Where this research is happening
-
Cedars-Sinai Medical Center
Los Angeles, United States Active
Researchers
- Principal investigator: Sutterwala, Fayyaz S. — Cedars-Sinai Medical Center
- Study coordinator: Sutterwala, Fayyaz S.
Related research
Other NIH-funded projects on the same topics.
-
Lipid signals that control acetyl-CoA and fat metabolism in NAFLD
A study exploring how membrane lipids influence acetyl-CoA metabolism to understand and potentially treat nonalcoholic fatty liver disease (NAFLD).
-
Them1’s role in fat metabolism and MASLD progression
Aims to understand how a fat-regulating protein (Them1) affects energy use in fat and liver, and how this could contribute to MASLD in people who are overweight.
-
Biomarker-guided Immunosuppression in Kidney Transplant Patients
A multicenter study in kidney transplant recipients is testing whether a biomarker score from HLA-DR/DQ can guide changes in immunosuppression to reduce rejection risk and drug toxicity.
-
Alpha5 integrin's role in ALS: how a cell switch worsens disease
Aims to understand how a specific protein called alpha5 integrin in immune cells affects ALS progression and whether blocking it can help extend life.
-
Chlamydia pneumoniae infection and Alzheimer's disease progression
This project looks at whether a common lung infection, Chlamydia pneumoniae, might influence Alzheimer's disease in people and what that could mean for treatment.
-
Them1 Inhibitors to Help Treat Fatty Liver Disease
Aims to develop and test small molecule drugs that block Them1 to help people with non-alcoholic fatty liver disease (NAFLD).
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.